Clinical Data MSD, Eisai report setback in first-line kidney cancer trial PharmaphorumThe LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma. Clinical DataOncologyRead full story Post navigation Previous: Gilead, Arcus tumble again in TIGIT, triggering 2 trial cullsNext: AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026